Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00094809
Other study ID # 20020715
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 1, 2003
Est. completion date January 23, 2008

Study information

Verified date September 2018
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with locally advanced or metastatic colorectal cancer. This study is considered to be "investigational" because the time between receiving pegfilgrastim and the next cycle of chemotherapy is only 11 days.


Other known NCT identifiers
  • NCT00119327

Recruitment information / eligibility

Status Completed
Enrollment 252
Est. completion date January 23, 2008
Est. primary completion date May 19, 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Locally advanced or metastatic colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy with curative intent.

- Histologically or cytologically documented locally advanced or metastatic colorectal cancer. The site of the primary lesion must be or has been confirmed endoscopically, radiologically, or surgically to be or has been in the large bowel.

- Measurable or evaluable disease.

- ECOG performance status 0, 1 or 2

- Life expectancy = 12 weeks

- All of the following: (1) = 4 weeks must have elapsed from the time of major surgery and subjects must have recovered from the effects (e.g., laparotomy); (2) = 2 weeks must have elapsed from the time of minor surgery and subjects must have recovered from the operation (insertion of a vascular access device is not considered major or minor surgery); (3) = 4 weeks must have elapsed from the time of major radiotherapy (e.g., chest or bone palliative radiation therapy).

- Subjects may have received prior adjuvant therapy and one prior chemotherapy regimen for metastatic disease providing 30 days has elapsed from last chemotherapy dose.

- Subject must have recovered from prior chemotherapy complications and in the opinion of the investigator, the subjects current status does not place the subject at risk for entry into the trial.

- Subjects with prior exposure to both oxaliplatin and irinotecan will not be eligible to participate in this study. However, if subject received prior therapy with oxaliplatin, they will be eligible to receive the FOLFIRI regimen. If subject received prior therapy with irinotecan, they will be eligible to receive the FOLFOX regimen.

- Age = 18 years

- Absolute neutrophil count = 1.5 x 109/L

- Platelet count =100 x 109/L

- Hemoglobin = 9.0 g/dL (subjects may be receive a red blood cell transfusion to achieve this requirement)

- Creatinine = 1.5 x UNL

- Total bilirubin = 1.5 mg/dL (= 25.65 µmol/L), regardless of whether subjects have liver involvement secondary to tumor

- Aspartate aminotransferase = 5 x UNL

- Alkaline phosphatase = 5 x UNL

- Informed consent to participate on the study.

Exclusion Criteria:

- Standard chemoradiation as adjuvant treatment for colorectal cancer will be allowed, but prior radiotherapy to >15% of bone marrow or outside of standard adjuvant colorectal cancer chemoradiation is not allowed.

- Known central nervous system metastases or carcinomatous meningitis.

- Predisposing colonic or small bowel disorders in which the symptoms are uncontrolled as indicated by baseline pattern of >3 loose stools daily in subjects without a colostomy or ileostomy. Subjects with a colostomy or ileostomy may be entered at the Investigator's discretion.

- Pleural effusion or ascites, which cause respiratory compromise (=Grade 2 dyspnea).

- Concurrent use of other investigational agents.

- No active infection requiring the start of systemic (intravenous or oral) anti-infective (antibiotic, antifungal, antiviral) within 72 hours of the administration of the first cycle of study chemotherapy.

- Symptomatic sensory peripheral neuropathy.

- The following conditions: Uncontrolled high blood pressure; unstable angina; symptomatic congestive heart failure; myocardial infarction = 6 months prior to randomization; serious uncontrolled cardiac arrhythmia; New York Heart Association classification III or IV.

- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancer from which the patient has been disease-free for at least five years.

- Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.

- Medical or psychiatric conditions which, in the opinion of the Investigator, make participation in an investigational trial of this nature a poor risk.

- Known sensitivity to E. coli derived products (e.g., Filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A) or known sensitivity to any of the products to be administered during dosing.

- Subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s).

- Subject of child-bearing potential is evidently pregnant (e.g., positive HCG test) or is breast feeding.

- Subject is not using adequate contraceptive precautions.

- Subject will not be available for follow-up assessment.

- Concerns for subject's compliance with the protocol procedures.

Study Design


Intervention

Drug:
Placebo
Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Pegfilgrastim
Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

References & Publications (1)

Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Grade 3 or 4 Neutropenia Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment First 4 cycles of treatment (8 weeks)
Primary Grade 4 Neutropenia Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment First 4 cycles of treatment (8 weeks)
Secondary Dose Delay or Reduction Due to Neutropenia Dose delay or reduction in chemotherapy doses due to neutropenia First 4 cycles of treatment (8 weeks)
Secondary Dose Delay or Reduction for Any Reason Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason First 4 cycles of treatment (8 weeks)
Secondary Febrile Neutropenia Febrile neutropenia, Defined as a temperature = 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. First 4 cycles of treatment (8 weeks)
Secondary Hospitalization Due to a Neutropenia-Related Event Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment First 4 cycles of neutropenia (8 weeks)
Secondary Progression-Free Survival Kaplan-Meier estimate of the median time to disease progression or death Up to 24 months after first four cycles of treatment
Secondary Objective Tumor Response Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. First 4 cycles of treatment (8 weeks)
Secondary Survival Death from any cause through the end of the follow-up period Up to 24 months after first four cycles of treatment
Secondary Antibiotic Use Due to Febrile Neutropenia Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. First 4 cycles of treatment (8 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A